Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Purity:
98.70%
CAS Number:
[745013-59-6]
Target:
Others|||Immunology/Inflammation related
T77466
* VAT and and shipping costs not included. Errors and price changes excepted